Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genomic Solutions-naz{GNSL} -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (85)	10/24/2001 12:03:22 PM
From: tuck	Respond to of 93

FWIW (yea, rah, yea, rah, man): >>ANN ARBOR, Mich., Oct. 24 /PRNewswire/ -- Genomic Solutions Inc. (Nasdaq: GNSL - news) announced that the company has sold its 500th major research system since January 1998. The sale was made by Genomic Solutions' distribution partner, PerkinElmer Life Sciences, to the University of Calgary. Genomic Solutions classifies major systems as instruments valued at $25,000 or more. ``The achievement of this sales milestone solidifies Genomic Solutions' position as a leading supplier of genomic and proteomic systems,'' notes Jeffrey Williams, President and CEO. ``It also underscores our commitment to the global life sciences marketplace.'' ``Furthermore, the Genomic Solutions product line has been well received by our customers,'' adds Shannon Richey, Executive Vice President for Marketing. ``Scientists have shared with us how our proteomic and genomic systems have helped them achieve success in their research.'' University of Calgary purchases an Investigator(TM) ProGest(TM) The 500th Genomic Solutions system, an Investigator ProGest Protein Digestion Station, was purchased by the Department of Physiology and Biophysics, Neuroscience Research Group, University of Calgary. The instrument automates the digestion of proteins in gel plugs and is part of the fully integrated Investigator Proteomic System. The University had previously purchased other Investigator components including a 2-D Electrophoresis System and a ProPic(TM) Robotic Workstation. According to Jens R. Coorssen, Ph.D., AHFMR/HSF Scholar at the University of Calgary, the Neuroscience Research Group has been very pleased with the performance of Genomic Solutions products and the support his lab has received from the company. ``Every time I turn around and have to talk to other companies about things, I'm so glad I made the right decision to do business with PerkinElmer and Genomic Solutions...folks who still know what 'science' means,'' Dr. Coorssen noted.<< snip >>Frankly, I have never really understood the magnitude of the slowdown in the sub-sector, despite your chronicle of events on TRICKLE. Its bad enough that I have been forced to accept the reality of the linkage between the NAZ and BT prices (which exists in part because the elephants like it that way). Now I need to comprehend that a slowdown in the economy results in a broad based slowdown in proteomic research? If we don't see a significant pickup in Q4 cap ex for genomic/proteomic equipment, I am going to be genuinely baffled.<< I hear you. I am watching the early trickle quarterly closely for clues about this. It appears the leading plays in proteomics to date have been the mass spec companies, certainly with regard to instrumentation. Of those, only ABI has reported (this AM), and I haven't listened to their conference call yet. Perhaps it is a good sign they've held up relatively well of late. However, both MDCC and ABI have made noises about macro environment and lack of visibility in their PRs. Three months ago, it was hoped the picture would be clearer. Sadly, Sept. 11 has torpedoed that little dream. Cheers, Tuck